 |
- Q Zhao, L Zhang, J Jiang, L Xu, J Shentu, D Liu, Y Xia, F Tan, Y Wang, D Zhang, P Hu. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC: results from a phase I/II trial. 2009, 13th Conference of Lung Cancer, San Francisco, CA, US.
- D Liu, L Zhang, J Jiang, F Tan, Y Wang, D Zhang, P Hu. Phase I studies of a novel oral EGFR inhibitor, icotinib in health male subjects. 2009, 13th Conference of Lung Cancer, San Francisco, CA, US.
- F Tan, L Zhang, Q Zhao, D Liu, Y Hu, Y Liu, L Ding, P Hu, Y Wang. Pharmacology and clinical evaluation of icotinib hydrochloride. Chinese J. of New Drugs, 2009, 18(8): 1-4.
- D Liu, J Jiang, P Hu, F Tan, Y Wang. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877(30): 3781-6.
- Z Guan, X Chen, Y Wang, D Zhang. Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22(14): 2176-84.
|
|
